PROCEPT (PRCT) EVP/CTO Barry Templin Receives RSUs & Stock Option Award

What Happened
Barry L. Templin, EVP and Chief Technology Officer of PROCEPT BioRobotics (PRCT), received equity awards on 2026-08-13: 26,246 restricted stock units (RSUs) and an award covering 36,312 derivative shares (stock option). Both awards were reported at $0.00 per share (standard for grants) and together represent 62,558 contingent shares subject to vesting and continued service.

Key Details

• Transaction date: 2026-08-13; filing date: 2026-08-14 (timely filing).
• Awards: 26,246 RSUs (reported as acquisition, $0.00) and 36,312 derivative shares (stock option award, reported as acquisition, $0.00).
• Shares owned after transaction: not disclosed in the filing.
• Vesting and terms (from footnotes):
  • RSUs: Each RSU equals one share if and when vested. 25% vests on Aug 13, 2027; the remaining awards vest in periodic installments over the following 36 months (subject to continued service). The RSU grant represents 50% of the expected 2027 grant value and was issued in lieu of that portion.
  • Stock option: 1/48th of the option vests monthly starting Aug 13, 2026, over four years, subject to continued employment. This option award likewise represents 50% of the expected 2027 grant value and was issued in lieu of that portion.
• No indication of a sale, cashless exercise, tax-withholding sale, 10b5-1 plan, or late filing was noted.

Context: These are standard compensation awards for an executive and are contingent on continued service and vesting schedules. Grants are not immediate stock purchases or sales and do not necessarily signal an immediate change in insider sentiment.